ASX:CMP 18 July 2025

March 20, 2026, 11:47 PM EDT. CSL (ASX:CSL) is expanding its Kankakee, Illinois site, boosting plasma therapy capacity with new Horizon 2 technology. Despite a 2.88% share price rise to A$138.50, the stock shows mixed signals. The 1-year shareholder return is 44.13%, but multi-year returns suggest pressure. Market watchers note a substantial valuation gap, with a fair value estimate at A$263.33 based on discounted cash flows reflecting growth in immunoglobulin therapies and margin recovery at CSL Behring. However, the price-to-earnings ratio of 33.7x is above biotech peers, hinting at a potential premium or correction. Investors should weigh projected growth against risks including tariff changes and execution challenges.